(Total Views: 436)
Posted On: 06/09/2025 5:51:31 AM
Post# of 154581
CAR-T
The most serious risk of CAR-T therapy is cytokine release syndrome (CRS), a potentially life-threatening immune reaction that can cause high fever, low blood pressure, organ failure, and even death if not managed promptly.
The most recent Roche buyout was the acquisition of Poseida Therapeutics, a San Diego-based developer of gene therapies and off-the-shelf CAR-T cell therapies. The deal, valued at up to $1.5 billion, included $9 per share in cash plus contingent milestone payments of up to $4 per share. The acquisition was completed in January 2025
The most serious risk of CAR-T therapy is cytokine release syndrome (CRS), a potentially life-threatening immune reaction that can cause high fever, low blood pressure, organ failure, and even death if not managed promptly.
The most recent Roche buyout was the acquisition of Poseida Therapeutics, a San Diego-based developer of gene therapies and off-the-shelf CAR-T cell therapies. The deal, valued at up to $1.5 billion, included $9 per share in cash plus contingent milestone payments of up to $4 per share. The acquisition was completed in January 2025
(4)
(0)
